This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BMY vs. AZN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BMY vs. AZN: Which Stock Is the Better Value Option?
Merck to Acquire Europe's Antelliq Group for $2.4 Billion
by Zacks Equity Research
Merck (MRK) secures an acquisition deal to purchase French animal health company Antelliq Group for a consideration of around $2.4 billion.
Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.
Novartis Presents Additional Data on Breast Cancer Candidate
by Zacks Equity Research
Novartis (NVS) presents supplementary data from phase III study on BYL719 in combination with Faslodex for the treatment of advanced breast cancer. The study scripts success in PFS.
AstraZeneca's Imfinzi Fails in Head and Neck Cancer Study
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi monotherapy and combination therapy fail to meet overall survival endpoint in phase III EAGLE study.
Pharma Stock Roundup: Glaxo's TESARO Buyout & Horlicks Sale, ASH Cancer Data Updates
by Zacks Equity Research
Glaxo (GSK) to buy TESARO and divest Horlicks brand to Unilever. ASH cancer presentations grab headilines.
Inovio (INO) to Receive Milestone Payment From AstraZeneca
by Zacks Equity Research
Inovio (INO) to receive an undeclared milestone amount from AstraZeneca following the initiation of dosing in a phase II combo inspection of the latter's MEDI0457 for treating HPV-related cancers.
Glaxo to Buy Zejula Maker TESARO for $5.1B, Stock Down 8%
by Zacks Equity Research
Glaxo (GSK) announces definitive deal to buy TESARO.
TESARO Shares Rally on Glaxo's $5.1 Billion Buyout Offer
by Zacks Equity Research
TESARO (TSRO) receives an acquisition offer from London-based pharma giant, Glaxo, valuing the company at $75 a share. Total value of the deal stands at $5.1 billion which includes acquisition of debt.
Astrazeneca's Fasenra Gets Orphan Drug for Autoimmune Disease
by Zacks Equity Research
AstraZeneca (AZN) gets Orphan Drug status for Fasenra in the United States for the treatment of eosinophilic granulomatosis with polyangiitis, a rare autoimmune disease.
The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca
Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs
by Zacks Equity Research
FDA grants approval to Pfizer's (PFE) new cancer drug and label expansion of AbbVie/Roche's Venclexta. CHMP gives nod to several drugs
BMY vs. AZN: Which Stock Is the Better Value Option?
by Zacks Equity Research
BMY vs. AZN: Which Stock Is the Better Value Option?
Clovis' (CLVS) Rubraca Gets Another US Patent, Shares Up
by Zacks Equity Research
Clovis Oncology's (CLVS) shares rise more than 5% following the issuance of a new patent for Rubraca in the United States for claims related to methods of treating cancer with its high dosage strength.
TESARO Shares Rally on Rumors of Potential Acquisition Offer
by Zacks Equity Research
Per a Bloomberg report, TESARO (TSRO) may have received an acquisition offer. Shares rally on rumors.
Pfizer's Bavencio Phase III Study for Ovarian Cancer Fails
by Zacks Equity Research
Pfizer's (PFE) late-stage advanced ovarian study on Bavencio (avelumab) fails to meet the primary endpoints.
Novartis (NVS) Gets FDA Nod for Label Expansion of Promacta
by Zacks Equity Research
Novartis (NVS) obtains FDA approval for the label expansion of Promacta. The CHMP also issues a positive opinion for the label expansion of Kisqali.
AstraZeneca's Imfinzi Fails in Lung Cancer Study, Stock Down
by Zacks Equity Research
AstraZeneca (AZN) announced that Imfinzi as a monotherapy or in combination with tremelimumab failed to improve overall survival in first-line NSCLC. The combination had also failed to improve progression free survival last year.
Top Analyst Reports for Union Pacific, UPS & American Tower
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Union Pacific (UNP), United Parcel Service (UPS) and American Tower (AMT).
Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings
by Zacks Equity Research
FDA provides updates on Merck (MRK), AstraZeneca (AZN) and Roche (RHHBY) for their cancer drugs. Bayer (BAYRY) reports strong third-quarter results.
AstraZeneca to Sell US Rights of Lung Infection Drug to Sobi
by Zacks Equity Research
AstraZeneca (AZN) to sell U.S. rights of Synagis to Sobi for an upfront consideration of $1.5 billion as it streamlines its portfolio
Tesaro, Clovis Rally on FDA Priority Review for Lynparza sNDA
by Zacks Equity Research
PARP inhibitor makers get a boost following priority review for AstraZeneca???s (AZN) label expansion application for Lynparza as a first-line maintenance treatment for ovarian cancer.
AstraZeneca's Lynparza Gets Priority Review in 1st Line Use
by Zacks Equity Research
AstraZeneca (AZN) and partner Merck's sNDA looking for label expansion of Lynparza in the first-line setting gets FDA's priority review.
Inovio (INO) Q3 Loss Narrower Than Expected, Revenues Meet
by Zacks Equity Research
Inovio Pharmaceuticals' (INO) Q3 loss betters estimates. Also, revenues match the consensus mark.
Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3
by Zacks Equity Research
Merrimack (MACK) discourages with Q3 loss, falling shy of estimates as well as deteriorates from the year-ago quarter's figure. Also, the company fails to reap any revenues in the period.